A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
Virchis A, Ganeshaguru K, Hart S, Jones D, Fletcher L, Wright F, Wickremasinghe R, Man A, Csermak K, Meyer T, Fabbro D, Champain K, Yap A, Prentice HG, Mehta A.
Virchis A, et al. Among authors: champain k.
Hematol J. 2002;3(3):131-6. doi: 10.1038/sj.thj.6200165.
Hematol J. 2002.
PMID: 12111648
Clinical Trial.